Pfizer Securities Received As Collateral decreased by 48.2% to $29.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 94.9%, from $564.00M to $29.00M.
Higher levels indicate increased activity in securities lending or repo markets, which can enhance yield but also increase counterparty exposure.
This represents the fair value of securities held by the company that were received from counterparties as collateral fo...
Common for large financial institutions; peers report this as part of their collateral management and liquidity disclosures.
current_assets_securities_received_as_collateral| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.00M | $236.00M | $341.00M | $755.00M | $1.50B | $530.00M | $366.00M | $256.00M | $274.00M | $288.00M | $129.00M | $564.00M | $43.00M | $56.00M | $29.00M |
| QoQ Change | — | +844.0% | +44.5% | +121.4% | +98.7% | -64.7% | -30.9% | -30.1% | +7.0% | +5.1% | -55.2% | +337.2% | -92.4% | +30.2% | -48.2% |
| YoY Change | — | — | — | >999% | +535.6% | +55.4% | -51.5% | -82.9% | -48.3% | -21.3% | -49.6% | +105.8% | -85.1% | -56.6% | -94.9% |